PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Massari, F.; Santoni, M.; Ciccarese, C.; Santini, D.; Alfieri, S.; Martignoni, G.; Brunelli, M.; Piva, F.; Berardi, R.; Montironi, R.; Porta, C.; Cascinu, S.; Tortora, G.
• Is Part Of: Cancer treatment reviews. Volume 41:Issue 2(2015)
• Page Start: 114
• Page End: 121
• Publication Date: 2015-02
• Subjects: Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2014.12.013
• Languages: English
• ISSNs: 0305-7372

Abstract

<abstract xml:lang="en" abstract-type="author-highlights" id="ab005"> <title id="st105">Highlights</title> <sec> <p id="sp0005"> <list id="l0005"> <list-item id="o0005"> <label></label> <p id="p0320">Evasion of immune surveillance, a process defined immune-editing, leads to RCC malignant progression.</p> </list-item> <list-item id="o0010"> <label></label> <p id="p0325">The PD-1/PD-L1 axis inhibition by targeted-antibodies, increases T-cell proliferation and anti-tumor activity.</p> </list-item> <list-item id="o0015"> <label></label> <p id="p0330">PD-1 and PD-L1 inhibitors have been tested in RCC, alone or combined with anti-VEGF/VEGFR drugs or other immunotherapies.</p> </list-item> <list-item id="o0020"> <label></label> <p id="p0335">We discuss the role of PD-1/PD-L1 in RCC, focusing on current clinical studies and future perspectives.</p> </list-item> </list> </p> </sec> </abstract>